Bence jones protein what's it describe with illustrative diagrams for 10 marks question for orthopaedic exam

Reading File

Finding Sources

Searching Images

Bence Jones protein multiple myeloma immunoglobulin light chain

Searching the Web

Bence Jones protein multiple myeloma light chain pathophysiology orthopaedic exam

Reading File

Finding Sources

Loading Image

Reading File

Loading Image

Searching Images

multiple myeloma lytic bone lesions skull X-ray plasma cell

Loading Image

Reading File

Loading Image

Reading File

Loading Image

I now have all the images and textbook content needed. Here is the complete 10-mark exam answer:

Bence Jones Protein — 10-Mark Orthopaedic Exam Answer

1. Definition

Bence Jones (BJ) protein refers to free monoclonal immunoglobulin light chains (either κ or λ type) produced in excess by a clone of neoplastic plasma cells. They are present in blood and are filtered by the kidney to appear in urine. Under normal circumstances, no Bence Jones protein is detectable in urine.

Named after Henry Bence Jones (1847), who first described the thermally precipitable urinary protein.

2. Cell of Origin & Molecular Structure

Normal plasma cells produce complete immunoglobulins (heavy + light chains). In malignant plasma cell disorders (particularly multiple myeloma), the neoplastic clone secretes:

Intact monoclonal immunoglobulin → detected as an M-spike on serum protein electrophoresis (SPEP)
Excess free light chains → BJ proteins, too small (MW ~22,000–44,000 Da) to be retained by glomeruli → filtered freely into urine

Complete Immunoglobulin:
   [Heavy chain] — [Heavy chain]
         |                |
   [Light chain]   [Light chain]

Bence Jones Protein = Free light chain only
   κ (kappa) or λ (lambda) monomer / dimer

Light chains are either κ or λ; in myeloma they are monoclonal (only one type), unlike the normal polyclonal mixture.

3. Disease Context — Multiple Myeloma (Orthopaedic Relevance)

Multiple myeloma is a malignant proliferation of plasma cells in bone marrow causing:

Feature	Details
Bone pain	Most common presenting symptom; vertebrae, ribs, skull, pelvis, femur
Lytic bone lesions	"Punched-out" defects on X-ray, 1–4 cm, no sclerotic rim
Pathological fractures	Most common in vertebrae; cause of acute back pain in elderly
Hypercalcaemia	Due to osteoclast activation → confusion, polyuria, constipation
Anaemia	Marrow replacement → normocytic normochromic anaemia
Renal failure	BJ protein nephrotoxicity → myeloma kidney
Infections	Suppression of normal immunoglobulins

Classic "CRAB" Criteria

C – hyperCalcaemia
R – Renal failure
A – Anaemia
B – Bone lesions

4. Pathogenesis of Bence Jones Proteinuria

Neoplastic plasma cell clone
         ↓
Excess free light chains produced
         ↓
Freely filtered at glomerulus (MW < 45,000 Da)
         ↓
Proximal tubule reabsorption overwhelmed
         ↓
BJ protein in urine (Bence Jones proteinuria)

Renal toxicity occurs by two mechanisms (Robbins Pathologic Basis of Disease):

Direct tubular toxicity — certain light chains (esp. λ6, λ3 families) are directly toxic to proximal tubular epithelial cells
Cast nephropathy — BJ proteins combine with Tamm-Horsfall glycoprotein under acidic conditions → large obstructive casts in distal/collecting tubules → inflammatory reaction → "myeloma kidney"

5. Radiological Illustration — Skull X-Ray

Classic "Punched-out" / "Pepper-pot" Skull

Multiple myeloma skull X-ray (lateral view) showing punched-out lytic lesions in the calvaria — Robbins, Cotran & Kumar Pathologic Basis of Disease, Fig. 13.21

Fig. 1 — Lateral skull radiograph demonstrating multiple sharply demarcated "punched-out" lytic lesions throughout the calvaria. No sclerotic rim. Generalised osteopenia is also present. This is the classical appearance of plasma cell myeloma on plain X-ray. (Source: Robbins, Cotran & Kumar Pathologic Basis of Disease)

Frontal skull view showing the same appearance:

Frontal skull X-ray showing numerous punched-out lytic lesions throughout the calvarium in multiple myeloma

Fig. 2 — AP skull radiograph: multiple discrete, rounded radiolucencies ("punched-out" lesions) scattered across the calvarium without a sclerotic rim. Diffuse osteopenia is also evident.

6. Bone Marrow Histology

Bone marrow aspirate in multiple myeloma showing abnormal plasma cells — Robbins, Cotran & Kumar, Fig. 13.22

Fig. 3 — Bone marrow aspirate (Wright–Giemsa stain). Normal marrow elements replaced by neoplastic plasma cells showing:

Eccentric nucleus with clock-face/cartwheel chromatin
Perinuclear hof (clearing due to prominent Golgi)
Multinucleated forms (plasmablasts)
Russell bodies (cytoplasmic globular inclusions of immunoglobulin)
Mott cells (grape-like cytoplasmic droplets)

(Source: Robbins, Cotran & Kumar Pathologic Basis of Disease)

7. Protein Electrophoresis — Detection of BJ Protein

Serum protein electrophoresis (SPEP) and immunofixation showing M-spike in myeloma — Robbins, Cotran & Kumar, Fig. 13.23

Fig. 4 — Serum protein electrophoresis (SP column) and immunofixation electrophoresis (IFE).

Normal serum (top): Polyclonal IgG appears as a broad diffuse band in the gamma region (arrow)
Patient serum (bottom): Single sharp monoclonal spike (arrowhead) in gamma region = M protein; confirmed by IFE as IgG κ — note sharp band crosses with anti-G and anti-κ lanes; polyclonal IgA and λ are suppressed

(Source: Robbins, Cotran & Kumar Pathologic Basis of Disease)

Urine Immunofixation for BJ protein:

Urine protein electrophoresis and immunofixation showing free kappa light chains (Bence Jones protein)

Fig. 5 — Urine protein electrophoresis (UPEP) showing free κ light chains (Bence Jones proteins) in the urine with a positive band in the kappa (κ) column and absent in the lambda (λ) column, confirming monoclonal κ free light chains.

8. Renal Pathology (Myeloma Kidney)

Gross specimen of myeloma kidney showing pale scarred cortex from light chain cast nephropathy

Fig. 6 — Gross photograph: three renal specimens. Left and centre kidneys show pale, scarred cortex with cortical destruction from chronic BJ protein deposition and cast nephropathy. Right kidney is normal for comparison.

Pathological sequence in Myeloma Kidney:

BJ protein filtered → tubular cast formation
      ↓
Obstruction of distal & collecting tubules
      ↓
Tubular cell toxicity & necrosis
      ↓
Inflammatory reaction (giant cell response)
      ↓
Tubular atrophy & interstitial fibrosis
      ↓
Progressive renal failure ("Myeloma Kidney")

9. Laboratory Diagnosis — Summary

Test	Finding
Urine BJ protein (heat test)	Precipitates at 45–60°C, redissolves at 100°C
Urine protein electrophoresis (UPEP)	Monoclonal light chain band
Urine immunofixation electrophoresis (IFE)	Gold standard — identifies κ or λ type
Serum free light chain (FLC) assay	Quantitative; κ:λ ratio abnormal
Serum protein electrophoresis (SPEP)	M-spike in gamma region
24-hour urine BJ protein	> 6 mg/dL significant; several grams/day in severe cases
Bone marrow biopsy	Plasma cells > 10–30% of cellularity

BJ proteinuria is present in 50–80% of multiple myeloma cases. It may be missed on routine dipstick (which detects albumin, not light chains) — electrophoresis and IFE are essential.

10. Associated Conditions

BJ proteinuria is also found in:

Macroglobulinaemia (Waldenström)
Primary (AL) amyloidosis — λ light chains (λ6, λ3 families) deposited as amyloid in tissues
Malignant lymphomas
MGUS (Monoclonal Gammopathy of Undetermined Significance) — precursor state

Summary Table for Quick Revision

Key Point	Detail
What is it?	Free monoclonal Ig light chain (κ or λ) in urine
Source	Neoplastic plasma cells in bone marrow
Key disease	Multiple myeloma (also MGUS, AL amyloidosis, lymphoma)
MW	~22,000–44,000 Da → freely glomerular filtered
Orthopaedic significance	Bone pain, pathological fractures, lytic lesions, hypercalcaemia
Classic X-ray	Punched-out lesions in skull/vertebrae — no sclerotic rim
Renal complication	Myeloma kidney (cast nephropathy) → renal failure
Best detection test	Urine immunofixation electrophoresis (IFE)
Heat test	Precipitates at 45–60°C, redissolves at 100°C (classic but insensitive)
Normal level in urine	None (absence is normal)

Sources: Robbins, Cotran & Kumar — Pathologic Basis of Disease (10th ed.); Henry's Clinical Diagnosis and Management by Laboratory Methods; Tietz Textbook of Laboratory Medicine (7th ed.)

There's no treatment in this add that too

Finding Sources

Searching PubMed

"multiple myeloma" treatment bortezomib lenalidomide

Searching the Web

multiple myeloma treatment guidelines 2024 bortezomib lenalidomide daratumumab bone disease bisphosphonates

Reading File

Finding Sources

Reading File

Loading Image

Here is the Treatment section to add to your answer:

11. Treatment of Multiple Myeloma (and BJ Proteinuria)

Treatment is divided into: (A) Anti-myeloma systemic therapy, (B) Bone disease management (orthopaedic relevance), and (C) Supportive/renal care.

A. Systemic Anti-Myeloma Therapy

Step 1 — Assess Transplant Eligibility

Newly Diagnosed Multiple Myeloma
              ↓
    ┌─────────────────────┐
    ↓                     ↓
Transplant candidate    Not transplant candidate
(age <65–70, fit)       (elderly, comorbid)

Treatment algorithm for newly diagnosed multiple myeloma — Goldman-Cecil Medicine

Fig. 7 — Treatment algorithm for newly diagnosed multiple myeloma. Transplant-eligible patients receive VRd induction → stem cell harvest → autologous transplant → maintenance. Non-eligible patients receive VRd or DRd until progression. (Source: Goldman-Cecil Medicine)

Drug Classes Used

Class	Agents	Mechanism
Proteasome inhibitors (PI)	Bortezomib (V), Carfilzomib (K)	Block ubiquitin-proteasome pathway → plasma cell apoptosis
Immunomodulatory drugs (IMiD)	Lenalidomide (R), Thalidomide	Anti-angiogenic, immune stimulation, plasma cell apoptosis
Corticosteroids	Dexamethasone (d)	Anti-inflammatory, direct cytotoxicity to plasma cells
Anti-CD38 monoclonal Ab	Daratumumab (D), Isatuximab	Target CD38 on plasma cells → complement/ADCC killing
Alkylating agents	Melphalan, Cyclophosphamide (Cy)	DNA crosslinking
CAR-T / BCMA-targeted	Idecabtagene vicleucel	Targets BCMA on plasma cells (relapsed/refractory)

Key Induction Regimens (Table 173-5, Goldman-Cecil Medicine)

Setting	Regimen	Details
Transplant eligible	VRd (standard)	Bortezomib 1.3 mg/m² IV + Lenalidomide 25 mg PO + Dexamethasone 40 mg × 3–4 cycles
Transplant eligible	DVRd (high-risk)	+ Daratumumab 16 mg/kg IV — ASCO 2026 guideline preferred
Non-transplant eligible	VRd × 6–9 months then lenalidomide maintenance	Or DRd (Daratumumab + Rd) until progression
Conditioning (ASCT)	Melphalan 200 mg/m²	Followed by autologous stem cell infusion

Maintenance (post-transplant)

Standard risk: Lenalidomide alone
High-risk cytogenetics (del17p, t[4;14]): Bortezomib + Lenalidomide

B. Bone Disease Management — Orthopaedic Focus

This is the most directly orthopaedic component of myeloma treatment.

Mechanism of Bone Destruction:
Neoplastic plasma cells
    ↓ secrete MIP-1α (CCL3), DKK-1, RANKL
    ↓
↑ Osteoclast activity + ↓ Osteoblast activity
    ↓
Lytic lesions → Pathological fractures + Hypercalcaemia

1. Bisphosphonates (First-line bone protection)

Drug	Dose	Route	Frequency
Zoledronic acid (Zometa)	4 mg	IV infusion over 15 min	Monthly × 2 years, then q3 months
Pamidronate	90 mg	IV infusion over 2 hours	Monthly

Mechanism: Inhibit farnesyl pyrophosphate synthase → osteoclast apoptosis → prevent bone resorption

Benefits:

Reduce skeletal-related events (SREs) — fractures, hypercalcaemia, cord compression
May have direct anti-myeloma activity
Zoledronic acid preferred (superior to pamidronate in trials)

⚠️ Complication: Osteonecrosis of the jaw (ONJ) — dental review mandatory before starting; avoid invasive dental procedures

2. RANKL inhibitor

Denosumab (anti-RANKL monoclonal antibody) — alternative to bisphosphonates, especially in renal impairment (does not require dose adjustment)

3. Radiation Therapy

Local palliative radiotherapy (20–30 Gy) for:
- Painful localised bone lesions unresponsive to systemic therapy
- Impending or actual pathological fracture (post-fixation)
- Spinal cord compression (emergency treatment)

4. Orthopaedic Surgery

Prophylactic intramedullary nailing — for impending pathological fractures (femur: Mirels score ≥ 9)
Vertebroplasty / Kyphoplasty — for painful vertebral compression fractures
Spinal decompression + stabilisation — for cord compression with instability
Arthroplasty — for destroyed femoral head/acetabulum

5. Hypercalcaemia Management

IV hydration (normal saline)
IV bisphosphonates / calcitonin (acute)
Corticosteroids (address underlying myeloma)

C. Renal (BJ Protein) Specific Management

Since BJ proteinuria is directly nephrotoxic, reducing the plasma cell burden is the primary goal:

Intervention	Rationale
Rapid anti-myeloma therapy (VRd/Bortezomib-based)	Reduces light chain production
Vigorous IV hydration	Prevents cast formation, dilutes tubular light chains
Urine alkalinisation	BJ protein + Tamm-Horsfall protein bind under acidic conditions; alkaline urine reduces cast formation
Avoid NSAIDs, contrast dye, nephrotoxins	Prevent AKI in at-risk kidney
Haemodialysis	For established myeloma kidney / ESRD
Plasmapheresis	Removes circulating free light chains acutely (in severe light chain crisis)

D. Supportive Care Summary

Problem	Management
Anaemia	Erythropoiesis-stimulating agents (EPO), transfusions
Infections	IVIG replacement; pneumococcal/flu vaccination; prophylactic aciclovir (with bortezomib)
DVT (with IMiDs)	Aspirin or LMWH prophylaxis
Peripheral neuropathy (bortezomib)	Dose reduction; switch to subcutaneous route
Bone pain	Analgesia, bisphosphonates, local radiotherapy

Treatment Response Monitoring

Serum M-protein (SPEP) — falls with effective treatment
24-hr urine BJ protein — decreases as plasma cell burden reduces
Serum free light chains — most sensitive marker
Bone marrow biopsy — assess minimal residual disease (MRD)
PET-CT / whole-body MRI — assess bone disease and extra-medullary disease

Complete Treatment Summary Diagram

MULTIPLE MYELOMA — TREATMENT OVERVIEW
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

SYSTEMIC THERAPY               BONE DISEASE
──────────────                 ────────────
Induction:                     Bisphosphonates:
  VRd or DVRd                    Zoledronic acid IV monthly
  (Bortezomib +                  Denosumab (renal impairment)
   Lenalidomide +              
   Dexamethasone               Radiotherapy:
   ± Daratumumab)                Local palliative RT
      ↓
ASCT (if eligible)             Surgery:
Melphalan 200 mg/m²              IMN for pathological # 
      ↓                          Kyphoplasty / vertebroplasty
Maintenance:                     Spinal stabilisation
  Lenalidomide
  (± Bortezomib if high-risk)  

RENAL PROTECTION               SUPPORTIVE
────────────────               ──────────
IV hydration                   EPO for anaemia
Urine alkalinisation           IVIG / antibiotics
Avoid nephrotoxins             DVT prophylaxis
Haemodialysis if ESRD          Pain management

Sources: Goldman-Cecil Medicine (International Edition); Harrison's Principles of Internal Medicine 22E (2025); Robbins, Cotran & Kumar — Pathologic Basis of Disease; ASCO-Ontario Health Living Guideline 2026 [PMID: 41494138]

This is a shared conversation. Sign in to Orris to start your own chat.